News
Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...
6h
TipRanks on MSNBayer’s New Clinical Study on HER2-Targeted Cancer Treatment: A Potential Game Changer
Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG has launched a Phase 2 clinical ...
Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...
Levelle Nutrition Co-founder and CEO Linda Alvarez discusses the timely launch of Cycle Syncing Protein and its broader ...
As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...
9h
Zacks Investment Research on MSNAbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
AbbVie ABBV holds a dominant position in the immunology market, which is being aided by strong sales of its two new ...
22h
Stockhead on MSNTryptamine secures landmark EEG biomarker deal to advance precision psychiatry
Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin ...
USD is seeking more than $293.5 million in funding for various projects over the years to come, for everything from ...
In the wake of funding cuts to mRNA vaccine research, we revisit a February story about a promising vaccine for pancreatic ...
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
In response to a proposal submitted by Ravenbhel Healthcare of the fixed dose combination (FDC) pulmonary drug Bilastine 10 ...
First-time disclosures session at ACS Fall 2025 reveals diverse candidates for treating sickle cell disease, heart failure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results